98%
921
2 minutes
20
The COVID-19 pandemic highlighted the significance of readily available and easily performed viral testing for surveillance during future infectious pandemics. The objectives of this study were: to assess the performance of the Xpert Xpress Flu and/or RSV test, a multiplex PCR assay for detecting influenza A and B virus and respiratory syncytial virus nucleic acids in respiratory tract specimens, relative to the Quidel Lyra Influenza A+B assay and the Prodesse ProFlu+ assay, and the system's ease of use by minimally trained operators. Overall, the Xpert Xpress Flu/RSV test demonstrated a high positive and negative percent agreement with the comparator assays, and was easy to use and interpret results, based on the operators' feedback. We concluded that the Xpert Xpress Flu/RSV test is sensitive, specific, and easy to use for the diagnosis of influenza and RSV by minimally trained operators and can be a valuable tool in future infectious clusters or pandemics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271353 | PMC |
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115764 | DOI Listing |
J Med Virol
July 2025
Clinical Virology, University Hospital Basel, Basel, Switzerland.
Rapid antigen diagnostic tests (RDTs) can rapidly detect respiratory pathogens, allowing for the prompt initiation of infection control measures and the prevention of nosocomial spread within hospital settings. In this study, we prospectively evaluated the diagnostic performance of a combined RDT from AllTest Biotech for the simultaneous detection of SARS-CoV-2, influenza virus (IV-A/B), and respiratory syncytial virus (RSV). We compared its diagnostic performance to the Xpert-Xpress-SARS-CoV-2/Flu/RSV molecular test using 100 naso-oropharyngeal swabs (Ct-values ≤ 35), collected from symptomatic patients with acute respiratory tract infections (RTIs) at our tertiary care hospital.
View Article and Find Full Text PDFJ Clin Virol
October 2025
Cepheid, CA, USA.
Background: Respiratory viruses are responsible for millions of healthcare visits annually. The unpredictable periodicity of Coronavirus disease 2019 and seasonal patterns of influenza and respiratory syncytial virus result in concurrent circulation of these viruses with non-specific and overlapping clinical symptoms.
Study Design: This study evaluated the Cepheid Xpert Xpress CoV-2/Flu/RSV plus test using 3011 nasopharyngeal swab (NPS) and 2943 anterior nasal (NS) specimens.
J Public Health Afr
July 2025
Centre for Research on Emerging and Re-emerging Diseases (CREMER), Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.
Background: New severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants may affect diagnostic test accuracy.
Aim: To evaluate the performance of two reverse transcription-polymerase chain reaction (RT-PCR) assays, DaAn Gene and Cepheid, for detecting Delta and Omicron variants.
Setting: Nasopharyngeal samples were collected in Yaoundé, Cameroon, between October 2021 and December 2022.
BMC Infect Dis
August 2025
Cepheid Inc, Sunnyvale, CA, US.
Background: Vaginitis is a major cause of healthcare visits in the US, costing over $1.2 billion annually. Point-of-care (POC) nucleic acid amplification tests (NAATs) could improve accuracy of diagnosis and treatment during initial visit for vaginitis compared to send-out NAATs.
View Article and Find Full Text PDFViruses
July 2025
National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
Since 2020, the Gs/Gd H5N1 influenza virus (clade 2.3.4.
View Article and Find Full Text PDF